IP

Inder Pal Malik

Active Director Director DIN 09675298
DIN 09675298 First appointment Jul 2022 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Jul 2022
Shareholding value •••• Premium profile

About Inder Pal Malik

Data last updated:

Inder Pal Malik is a Director at Libraw Pharma Excipients Private Limited (since 2022). The company operates in Pharma. Libraw Pharma Excipients Private Limited reported revenue of ₹30.37 Cr (FY 2025).

DIN 09675298
Primary Designation Director
Industry Pharma
First Appointment 15 Jul 2022
Oldest Company Age 4 yrs
Largest company Libraw Pharma Excipients Private Limited · ₹30.37 Cr (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director15 Jul 20222022₹30.37 Cr (FY 2025)Active

Board colleagues of Inder Pal Malik

Directorship timeline

Open interactive timeline →
Libraw Pharma Excipients Private Limited
Premium access

Shareholding and investment profile for Inder Pal Malik

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Inder Pal Malik

Inder Pal Malik currently holds 1 directorship: Libraw Pharma Excipients Private Limited (Director, since 15 Jul 2022, revenue ₹30.37 Cr (FY 2025)).

Inder Pal Malik was first appointed on 15 Jul 2022 as Director at Libraw Pharma Excipients Private Limited.

The current boards of Inder Pal Malik's companies include Dhruv Malik (Libraw Pharma Excipients Private Limited), Shuchi Malik (Libraw Pharma Excipients Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available